MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.4% – What’s Next?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) shares were down 3.4% on Thursday . The company traded as low as $2.36 and last traded at $2.57. Approximately 120,695 shares changed hands during trading, a decline of 59% from the average daily volume of 292,118 shares. The stock had previously closed at $2.66.

MAIA Biotechnology Price Performance

The company has a market capitalization of $60.01 million, a PE ratio of -1.54 and a beta of 0.31.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.16. On average, equities analysts anticipate that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current fiscal year.

Institutional Trading of MAIA Biotechnology

Several hedge funds have recently modified their holdings of the company. Mather Group LLC. boosted its position in shares of MAIA Biotechnology by 50,150.0% in the 2nd quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock worth $41,000 after purchasing an additional 12,036 shares in the last quarter. Ground Swell Capital LLC acquired a new position in MAIA Biotechnology during the 2nd quarter valued at about $56,000. Finally, Virtu Financial LLC acquired a new position in MAIA Biotechnology during the 1st quarter valued at about $71,000. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.